Home pharmaceuticals
 

Keywords :   


Tag: pharmaceuticals

Arena Pharmaceuticals: Belviq Sales Take A Modest Dip With Holiday

2014-11-22 23:40:00| Biotech - Topix.net

The anti-obesity pill Belviq from Arena Pharmaceuticals saw a modest 1.5% dip in sales with the reporting of this week's numbers. The dip can be attributed to the seasonality of weight loss products as well as the fact that Veterans Day happened during the reported week.

Tags: with sales holiday arena

 

AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods

2014-11-13 19:01:24| Biotech - Topix.net

Isis Pharmaceuticals and AstraZeneca today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively.

Tags: methods delivery targeted pharmaceuticals

 
 

Ironwood Pharmaceuticals Initiates Phase III Trial Of 72 mcg Linaclotide In Adult Patients With Chronic Idiopathic Constipation

2014-11-05 05:57:43| drugdiscoveryonline Home Page

Ironwood Pharmaceuticals, Inc. announced recently the initiation of a Phase III clinical trial in the U.S. evaluating a 72 mcg capsule of linaclotide to be taken once per day for the treatment of adults suffering from chronic idiopathic constipation (CIC)

Tags: iii trial adult phase

 

Dechra Pharmaceuticals plc Given "Buy" Rating at FinnCap

2014-10-26 03:06:46| Automakers - Topix.net

's stock had its "buy" rating reiterated by equities researchers at FinnCap in a research report issued on Friday. They currently have a GBX 800 target price on the stock.

Tags: buy rating plc pharmaceuticals

 

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

2014-10-10 04:59:10| Biotech - Topix.net

Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy . "ISIS-TTRRx is the most advanced drug in our collaboration with GSK, and aside from KYNAMRO, it is also the furthest advanced in our late-stage clinical pipeline.

Tags: study million advance phase

 

Sites : [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] next »